scispace - formally typeset
K

Karen R. Cleary

Researcher at University of Texas MD Anderson Cancer Center

Publications -  158
Citations -  20952

Karen R. Cleary is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Adenocarcinoma & Metastasis. The author has an hindex of 67, co-authored 158 publications receiving 20453 citations. Previous affiliations of Karen R. Cleary include University of Texas Health Science Center at Houston & University of Florida.

Papers
More filters
Journal ArticleDOI

Rationale for En Bloc Vein Resection in the Treatment of Pancreatic Adenocarcinoma Adherent to the Superior Mesenteric-Portal Vein Confluence

TL;DR: The data suggest that venous involvement is a function of tumor location rather than an indicator of aggressive tumor biology, and when necessary, segmental resection of the SMPV confluence may be performed safely during pancreaticoduodenectomy for periampullary malignant tumors.
Journal Article

Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.

TL;DR: The results show that STK15 is overexpressed in pancreatic tumors and carcinoma cell lines and suggest that overexpression of STK 15 may play a role in Pancic carcinogenesis.
Journal ArticleDOI

Vessel Counts and Expression of Vascular Endothelial Growth Factor as Prognostic Factors in Node-Negative Colon Cancer

TL;DR: Vessel count and expression of VEGF may be useful for predicting distant recurrence in patients with node-negative colon cancer.
Journal ArticleDOI

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

TL;DR: The goal of this study was to analyze the effects of different preoperative chemoradiotherapy schedules, intraoperative radiation therapy, patient factors, and histopathologic variables on survival duration and patterns of treatment failure in patients who underwent pancreaticoduodenectomy for adenocarcinoma of the pancreatic head.
Journal ArticleDOI

Preoperative infusional chemoradiation therapy for stage T3 rectal cancer

TL;DR: In this article, the authors evaluated preoperative infusional chemoradiation for patients with operable rectal cancer, using 5-fluorouracil (5-FU) and daily irradiation (45 Gy/25 fractions/5 weeks).